Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun:81:104461.
doi: 10.1016/j.breast.2025.104461. Epub 2025 Mar 24.

Towards precision therapy in HER2-positive early-stage breast cancer

Serena Di Cosimo  1 , Paolo Verderio  2
Affiliations
Editorial

Towards precision therapy in HER2-positive early-stage breast cancer

Serena Di Cosimo et al. Breast. 2025 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships that may be considered potential competing interests: Serena Di Cosimo reported receiving an institutional grant (IG 20774) from the Fondazione Associazione Italiana per la Ricerca sul Cancro (AIRC); funding from the Cancer Can.Heal European EU4Health Programme (101080009 - European Commission); serving as an “ad hoc” medical monitor for Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain); as well as support for attending meetings and/or travel from Daiichi Sankyo, and participation in an advisory board for Pfizer. Paolo Verderio and Serena Di Cosimo are leading the PNRR-POC-2023-12378113 project, founded by the European Union - Next Generation EU – PNRR M6C2 – Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedical del SSN, titled “A Composite Assay for HER2-Positive Early-Stage Breast Cancer Management”.

References

    1. Early Breast Cancer Trialists’ Collaborative group (EBCTCG) Trastuzumab for early-stage,HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139–1150. doi: 10.1016/S1470-2045(21)00288-6. - DOI - PMC - PubMed
    1. Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast. 2022;62(Suppl 1):S12–S16. doi: 10.1016/j.breast.2022.01.006. - DOI - PMC - PubMed
    1. Prat A., Guarneri V., Paré L., et al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncol. 2020;21(11):1455–1464. doi: 10.1016/S1470-2045(20)30450-2. - DOI - PMC - PubMed
    1. Prat A., Guarneri V., Pascual T., et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine. 2022;75 doi: 10.1016/j.ebiom.2021.103801. - DOI - PMC - PubMed
    1. Verderio P., Mangia A., Ciniselli C.M., Tagliabue P., Paradiso A. Biomarkers for early cancer detection - methodological aspects. Breast Care. 2010;5:62–65. doi: 10.1159/000303956. - DOI - PMC - PubMed

Publication types